Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET

MLA

Murali Kesavan, et al. “Long-Term Hematologic Toxicity of 177Lu-Octreotate-Capecitabine-Temozolomide Therapy of GEPNET.” Endocrine-Related Cancer, vol. 28, July 2021, pp. 521–27. EBSCOhost, https://doi.org/10.1530/erc-21-0082.

APA

Murali Kesavan, Phillip G. Claringbold, J. Harvey Turner, Piyush Grover, & Wei Sen Lam. (2021). Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. Endocrine-Related Cancer, 28, 521–527. https://doi.org/10.1530/erc-21-0082

Chicago

Murali Kesavan, Phillip G. Claringbold, J. Harvey Turner, Piyush Grover, and Wei Sen Lam. 2021. “Long-Term Hematologic Toxicity of 177Lu-Octreotate-Capecitabine-Temozolomide Therapy of GEPNET.” Endocrine-Related Cancer 28 (July): 521–27. doi:10.1530/erc-21-0082.